Friday, November 05, 2021 6:16:33 AM
The real reason is probably to be ready for increasing patient demand, and not start that flood before they have their “steps” aligned. (Everyone has seen the results of companies that start commercialization off on the wrong foot.)
My guess is your going to claim it’s because this has never been about biological therapeutic approval, and that you think it’s simply for Toucan to sell another manufacturing business.
If your conjecture that this was really a “scam” was hard to disprove in the past, it’s getting easier to dispel based on the increasing weight of new guidelines, SAP/endpoint development/overseas acceptance, 13 months of Journal preparation, changes in GBM definition, loss of prior competitor treatments, failure of competitor trials, accommodations from NICE regarding interim solution after Orbis/regulator early approvals, market cap maintained around one billion for over a year, continuing faith by Michael Bigger, increasing need for replacement SOC, MOA of DCVax-l as it relates to newly defined GBM, etc.
Your scam argument gets thinner by the day, but that said, everyone, even LP acknowledges this is an unbelievably long wait for patients, caregivers and investors. One of nwbo’s own board members already passed on a few years ago, and they (and we) are not getting any younger. Time marches on.
My guess is your going to claim it’s because this has never been about biological therapeutic approval, and that you think it’s simply for Toucan to sell another manufacturing business.
If your conjecture that this was really a “scam” was hard to disprove in the past, it’s getting easier to dispel based on the increasing weight of new guidelines, SAP/endpoint development/overseas acceptance, 13 months of Journal preparation, changes in GBM definition, loss of prior competitor treatments, failure of competitor trials, accommodations from NICE regarding interim solution after Orbis/regulator early approvals, market cap maintained around one billion for over a year, continuing faith by Michael Bigger, increasing need for replacement SOC, MOA of DCVax-l as it relates to newly defined GBM, etc.
Your scam argument gets thinner by the day, but that said, everyone, even LP acknowledges this is an unbelievably long wait for patients, caregivers and investors. One of nwbo’s own board members already passed on a few years ago, and they (and we) are not getting any younger. Time marches on.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
